secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001628280-25-045215
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 3.03, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences ends AIH program after FDA setback, begins strategic review
-------------------------------------------------------------------------------

- FDA cancelled Type C meeting for zetomipzomib in autoimmune hepatitis; requires PK study causing ~2-year delay and 48-hour in-unit monitoring.
- Company to explore strategic alternatives, retain TD Cowen; restructuring includes workforce reduction and cost containment.
- Preliminary cash, equivalents and marketable securities of $90.2M as of Sep 30, 2025 (unaudited).
- Rights plan amended to extend expiration to after 2026 annual meeting (or 2027 if ratified); not in response to takeover threat.
- PORTOLA final data still to be presented at The Liver Meeting Nov 10, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000162828025045215/0001628280-25-045215-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000162828025045215/kzr-20251016.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-045215

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer